Literature DB >> 20937871

IL-33 is a crucial amplifier of innate rather than acquired immunity.

Keisuke Oboki1, Tatsukuni Ohno, Naoki Kajiwara, Ken Arae, Hideaki Morita, Akina Ishii, Aya Nambu, Takaya Abe, Hiroshi Kiyonari, Kenji Matsumoto, Katsuko Sudo, Ko Okumura, Hirohisa Saito, Susumu Nakae.   

Abstract

IL-33, a member of the IL-1-related cytokines, is considered to be a proallergic cytokine that is especially involved in Th2-type immune responses. Moreover, like IL-1α, IL-33 has been suggested to act as an "alarmin" that amplifies immune responses during tissue injury. In contrast to IL-1, however, the precise roles of IL-33 in those settings are poorly understood. Using IL-1- and IL-33-deficient mice, we found that IL-1, but not IL-33, played a substantial role in induction of T cell-mediated type IV hypersensitivity such as contact and delayed-type hypersensitivity and autoimmune diseases such as experimental autoimmune encephalomyelitis. Most notably, however, IL-33 was important for innate-type mucosal immunity in the lungs and gut. That is, IL-33 was essential for manifestation of T cell-independent protease allergen-induced airway inflammation as well as OVA-induced allergic topical airway inflammation, without affecting acquisition of antigen-specific memory T cells. IL-33 was significantly involved in the development of dextran-induced colitis accompanied by T cell-independent epithelial cell damage, but not in streptozocin-induced diabetes or Con A-induced hepatitis characterized by T cell-mediated apoptotic tissue destruction. In addition, IL-33-deficient mice showed a substantially diminished LPS-induced systemic inflammatory response. These observations indicate that IL-33 is a crucial amplifier of mucosal and systemic innate, rather than acquired, immune responses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20937871      PMCID: PMC2972966          DOI: 10.1073/pnas.1003059107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression.

Authors:  M J Sweet; B P Leung; D Kang; M Sogaard; K Schulz; V Trajkovic; C C Campbell; D Xu; F Y Liew
Journal:  J Immunol       Date:  2001-06-01       Impact factor: 5.422

2.  Occupational asthma after inhalation of dust of the proteolytic enzyme, papain.

Authors:  J Milne; S Brand
Journal:  Br J Ind Med       Date:  1975-11

3.  A novel IkappaB protein, IkappaB-zeta, induced by proinflammatory stimuli, negatively regulates nuclear factor-kappaB in the nuclei.

Authors:  S Yamazaki; T Muta; K Takeshige
Journal:  J Biol Chem       Date:  2001-05-16       Impact factor: 5.157

4.  Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice.

Authors:  Salah-Eddine Lamhamedi-Cherradi; Shi-Jun Zheng; Kimberly A Maguschak; Jacques Peschon; Youhai H Chen
Journal:  Nat Immunol       Date:  2003-02-10       Impact factor: 25.606

5.  Continuous exposure to house dust mite elicits chronic airway inflammation and structural remodeling.

Authors:  Jill R Johnson; Ryan E Wiley; Ramzi Fattouh; Filip K Swirski; Beata U Gajewska; Anthony J Coyle; José-Carlos Gutierrez-Ramos; Russ Ellis; Mark D Inman; Manel Jordana
Journal:  Am J Respir Crit Care Med       Date:  2003-11-03       Impact factor: 21.405

Review 6.  IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma.

Authors:  D E Smith
Journal:  Clin Exp Allergy       Date:  2009-11-03       Impact factor: 5.018

7.  Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein IkappaBzeta.

Authors:  Masahiro Yamamoto; Soh Yamazaki; Satoshi Uematsu; Shintaro Sato; Hiroaki Hemmi; Katsuaki Hoshino; Tsuneyasu Kaisho; Hirotaka Kuwata; Osamu Takeuchi; Koichiro Takeshige; Tatsuya Saitoh; Shoji Yamaoka; Naoki Yamamoto; Shunsuke Yamamoto; Tatsushi Muta; Kiyoshi Takeda; Shizuo Akira
Journal:  Nature       Date:  2004-07-08       Impact factor: 49.962

8.  ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance.

Authors:  Elizabeth K Brint; Damo Xu; Haiying Liu; Aisling Dunne; Andrew N J McKenzie; Luke A J O'Neill; Foo Y Liew
Journal:  Nat Immunol       Date:  2004-03-07       Impact factor: 25.606

9.  Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses.

Authors:  Susumu Nakae; Yutaka Komiyama; Aya Nambu; Katsuko Sudo; Michiko Iwase; Ikuo Homma; Kenji Sekikawa; Masahide Asano; Yoichiro Iwakura
Journal:  Immunity       Date:  2002-09       Impact factor: 31.745

10.  The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function.

Authors:  K Hoshino; S Kashiwamura; K Kuribayashi; T Kodama; T Tsujimura; K Nakanishi; T Matsuyama; K Takeda; S Akira
Journal:  J Exp Med       Date:  1999-11-15       Impact factor: 14.307

View more
  251 in total

1.  F-box protein FBXL19-mediated ubiquitination and degradation of the receptor for IL-33 limits pulmonary inflammation.

Authors:  Jing Zhao; Jianxin Wei; Rachel K Mialki; Daniel F Mallampalli; Bill B Chen; Tiffany Coon; Chunbin Zou; Rama K Mallampalli; Yutong Zhao
Journal:  Nat Immunol       Date:  2012-06-03       Impact factor: 25.606

2.  Dusp5 negatively regulates IL-33-mediated eosinophil survival and function.

Authors:  Derek A Holmes; Jung-Hua Yeh; Donghong Yan; Min Xu; Andrew C Chan
Journal:  EMBO J       Date:  2014-11-14       Impact factor: 11.598

Review 3.  Interleukin-33 biology with potential insights into human diseases.

Authors:  Gaby Palmer; Cem Gabay
Journal:  Nat Rev Rheumatol       Date:  2011-04-26       Impact factor: 20.543

Review 4.  Innate immunity in the central nervous system.

Authors:  Richard M Ransohoff; Melissa A Brown
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

5.  IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G.

Authors:  Emma Lefrançais; Stephane Roga; Violette Gautier; Anne Gonzalez-de-Peredo; Bernard Monsarrat; Jean-Philippe Girard; Corinne Cayrol
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

6.  Dysbiosis-induced IL-33 contributes to impaired antiviral immunity in the genital mucosa.

Authors:  Ji Eun Oh; Byoung-Chan Kim; Dong-Ho Chang; Meehyang Kwon; Sun Young Lee; Dukjin Kang; Jin Young Kim; Inhwa Hwang; Je-Wook Yu; Susumu Nakae; Heung Kyu Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-25       Impact factor: 11.205

7.  Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling.

Authors:  Jennifer E Ho; Wei-Yu Chen; Ming-Huei Chen; Martin G Larson; Elizabeth L McCabe; Susan Cheng; Anahita Ghorbani; Erin Coglianese; Valur Emilsson; Andrew D Johnson; Stefan Walter; Nora Franceschini; Christopher J O'Donnell; Abbas Dehghan; Chen Lu; Daniel Levy; Christopher Newton-Cheh; Honghuang Lin; Janine F Felix; Eric R Schreiter; Ramachandran S Vasan; James L Januzzi; Richard T Lee; Thomas J Wang
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

8.  IL-33 Signaling Protects from Murine Oxazolone Colitis by Supporting Intestinal Epithelial Function.

Authors:  Amanda Waddell; Jefferson E Vallance; Preston D Moore; Amy T Hummel; David Wu; Shiva K Shanmukhappa; Lin Fei; M Kay Washington; Phillip Minar; Lori A Coburn; Susumu Nakae; Keith T Wilson; Lee A Denson; Simon P Hogan; Michael J Rosen
Journal:  Inflamm Bowel Dis       Date:  2015-12       Impact factor: 5.325

9.  CXCR6+ST2+ memory T helper 2 cells induced the expression of major basic protein in eosinophils to reduce the fecundity of helminth.

Authors:  Kazushige Obata-Ninomiya; Kenji Ishiwata; Hisanobu Nakano; Yusuke Endo; Tomomi Ichikawa; Atsushi Onodera; Kiyoshi Hirahara; Yoshitaka Okamoto; Hirotaka Kanuka; Toshinori Nakayama
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-01       Impact factor: 11.205

10.  Exophilin-5 regulates allergic airway inflammation by controlling IL-33-mediated Th2 responses.

Authors:  Katsuhide Okunishi; Hao Wang; Maho Suzukawa; Ray Ishizaki; Eri Kobayashi; Miho Kihara; Takaya Abe; Jun-Ichi Miyazaki; Masafumi Horie; Akira Saito; Hirohisa Saito; Susumu Nakae; Tetsuro Izumi
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.